scholarly journals Papillary Thyroid Cancer Differentiating Into Anaplastic Carcinoma With Near-Complete Response to Targeted Dabrafenib/Trametinib Combination Therapy

Cureus ◽  
2021 ◽  
Author(s):  
Pruthali Kulkarni ◽  
James Hall ◽  
Liping Wang ◽  
Sherronda Henderson
Keyword(s):  
Thyroid Cancer ◽  
Combination Therapy ◽  
Papillary Thyroid Cancer ◽  
Complete Response ◽  
Anaplastic Carcinoma ◽  
Papillary Thyroid

BRAF-positive paucicellular variant of anaplastic carcinoma in the presence of tall cell variant papillary thyroid cancer

2017 ◽  
Vol 79 (3) ◽  
pp. 27
Author(s):  
O. V. Dolzhansky ◽  
E. M. Paltseva ◽  
D. N. Khmelkova ◽  
F. A. Konovalov ◽  
I. V. Kanivets ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Anaplastic Carcinoma ◽  
Papillary Thyroid ◽  
Tall Cell Variant ◽  
Tall Cell ◽  
Cell Variant

scholarly journals Effects of Anti-Cancer Drug Sensitivity-Related Genetic Differences on Therapeutic Approaches in Refractory Papillary Thyroid Cancer

2022 ◽  
Vol 23 (2) ◽  
pp. 699
Author(s):  
Hyeok Jun Yun ◽  
Minki Kim ◽  
Sang Yong Kim ◽  
Sungsoon Fang ◽  
Yonjung Kim ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Combination Therapy ◽  
Papillary Thyroid Cancer ◽  
Thyroid Tissue ◽  
Cancer Drug ◽  
Papillary Thyroid ◽  
Anti Cancer ◽  
Well Differentiated

Thyroid cancer (TC) includes tumors of follicular cells; it ranges from well differentiated TC (WDTC) with generally favorable prognosis to clinically aggressive poorly differentiated TC (PDTC) and undifferentiated TC (UTC). Papillary thyroid cancer (PTC) is a WDTC and the most common type of thyroid cancer that comprises almost 70–80% of all TC. PTC can present as a solid, cystic, or uneven mass that originates from normal thyroid tissue. Prognosis of PTC is excellent, with an overall 10-year survival rate >90%. However, more than 30% of patients with PTC advance to recurrence or metastasis despite anti-cancer therapy; consequently, systemic therapy is limited, which necessitates expansion of improved clinical approaches. We strived to elucidate genetic distinctions due to patient-derived anti-cancer drug-sensitive or -resistant PTC, which can support in progress novel therapies. Patients with histologically proven PTC were evaluated. PTC cells were gained from drug-sensitive and -resistant patients and were compared using mRNA-Seq. We aimed to assess the in vitro and in vivo synergistic anti-cancer effects of a novel combination therapy in patient-derived refractory PTC. This combination therapy acts synergistically to promote tumor suppression compared with either agent alone. Therefore, genetically altered combination therapy might be a novel therapeutic approach for refractory PTC.

Abstract #1086: Patient Experience with Severe Low Energy Following Total Thyroidectomy for Papillary Thyroid Cancer

2017 ◽  
Vol 23 ◽  
pp. 258
Author(s):  
Elizabeth Wendt ◽  
Maria Bates ◽  
Reese Randle ◽  
Jason Orne ◽  
Cameron Macdonald ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Total Thyroidectomy ◽  
Papillary Thyroid Cancer ◽  
Patient Experience ◽  
Low Energy ◽  
Papillary Thyroid
Sign in / Sign up

Export Citation Format

Share Document